Certain TruSight Tumor 170 bundle kits have been discontinued, including TruSight Tumor 170 with NextSeq 500/550 v2 sequencing reagents (Cat. No. OP-101-1003 and 20018621), TruSight Tumor 170 plus Pierian Interpretation reports (Cat. No. 20032628), and TruSight Tumor 170 with NextSeq v2.5 Reagents plus Pierian interpretation reports (Cat. No. 20032629). TruSight Tumor 170 plus Watson for Genomics (Cat. No. 20018622) has also been discontinued; if you require that analysis, you can continue to work with IBM directly. Recommended replacement products: TruSight Tumor 170 Kit with NextSeq v2.5 Reagents (Cat. No. 20028821) and TruSight Tumor 170 Kit (24 Samples) (Cat. No. OP-101-1004).
TruSight Tumor 170
Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.
Read More...
Product Highlights
TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.
- Comprehensive Coverage of Cancer-Related Variants
Assessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications in one assay using DNA and RNA creates efficiencies in sample usage, time, and cost.
- Accurate Results from Low-Quality Samples1
Variant detection with as little as 40 ng DNA and RNA input, and as low as 5% mutant allele frequency, maximizes the results from precious formalin-fixed paraffin-embedded (FFPE) samples. - Integrated, Streamlined Workflow
DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis.
Fast, Automation-friendly Workflow
Prepare libraries for Illumina sequencing in less than a day. Illumina Qualified Methods are available on a range of automation platforms through our partners.
Frequently Purchased Together
Specifications
Project Recommendations
| Instrument | Recommended Number of Samples | Read Length |
|---|---|---|
| NextSeq 550 System | Samples per run (high output): 16 (8 DNA + 8 RNA), 10 if DNA only, 16 if RNA only | 2 × 101 bp (max recommended) |
Scientific Posters
AACR 2017: TruSight Tumor 170 and Solid Tumor Profiling Analytical Performance with FFPE Samples
Standard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85% of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.
AACR 2017: TruSight Tumor 170 for Small Nucleotide Variations and Gene Amplifications in FFPE DNA Samples
TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.
AACR 2017: TruSight Tumor 170 for Fusions and Splice Variants in FFPE RNA Tumor Samples
Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.
Product Literature
Assessing DNA and RNA Quality from FFPE Samples for TruSight Tumor 170
White paper | PDF < 1 MB
Detection of low-frequency variants in cfDNA using TruSight Tumor 170 with the TruSight UMI Toolkit
Application note | PDF 2 MB
Application note | PDF 2 MB
Data sheet | PDF | 6 versions
product_file | EXCEL < 1 MB
A dedicated support section is not currently available for this product
TruSight Oncology 500
Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI, and HRD) from FFPE tissue.
TruSight RNA Pan-Cancer
Targeting 1385 cancer genes for gene expression, variant, and fusion detection studies in many RNA sample types including blood, bone marrow, and formalin-fixed, paraffin-embedded (FFPE) tissue.
TruSight RNA Fusion Panel
Comprehensive gene fusion detection covering 507 genes from FFPE and other cancer research samples.
References
- Beta study. Data on file. March 2017.